预约演示
更新于：2024-12-26
Padeliporfin
帕利泊芬
更新于：2024-12-26
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2017-11-10), |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C37H41KN5O9PdS |
InChIKeyIBWLFZJHPWKXBT-XLYVRUQKSA-L |
CAS号698393-30-5 |
关联
21
项与 帕利泊芬 相关的临床试验NCT05918783
A Multicenter Open-label Phase 1/1b Study to Evaluate Safety, Feasibility and Early Treatment Effect of Padeliporfin VTP Using Robotic Assisted Bronchoscopy and Cone Beam CT Guidance in Patients With Peripheral Lung Cancer
Phase 1/1b, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects.
Patients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom surgical treatment is planned, will be recruited. Surgery will be performed at 5-21 days following the VTP procedure.
Study intervention: robotic assisted bronchoscopic Padeliporfin VTP lung ablation: vascular targeted photodynamic therapy using Padeliporfin photosensitizer.
Patients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom surgical treatment is planned, will be recruited. Surgery will be performed at 5-21 days following the VTP procedure.
Study intervention: robotic assisted bronchoscopic Padeliporfin VTP lung ablation: vascular targeted photodynamic therapy using Padeliporfin photosensitizer.
开始日期2024-12-28 |
申办/合作机构 |
NCT05919238
A Multicenter Open-label Phase 1 Trial to Evaluate Safety and Preliminary Efficacy of Endovascularly Applied Vascular Targeted Photodynamic Therapy (VTP) for Patients With Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma
This is a prospective, multicenter, non-randomized, open label light dose escalation phase I trial to evaluate the safety and preliminary efficacy of Padeliporfin vascular targeted photodynamic therapy (VTP) applied via endovascular fiber placement within a dilatation catheter, through the superior mesenteric artery (SMA) in patients with stage III, locally advanced (LA) unresectable pancreatic ductal adenocarcinoma (PDAC). The investigators will evaluate safety and preliminary efficacy of Padeliporfin VTP administered endovascularly using light dose escalation.
开始日期2024-05-15 |
申办/合作机构 |
NCT04620239
Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (Padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer
This is a phase 3, open label, single arm study of padeliporfin in the treatment of Upper Tract Urothelial Carcinoma (UTUC). The ENLIGHTED study will recruit patients with low-grade non-invasive upper tract urothelial carcinoma in either the kidney or the ureter. Patients will be treated with padeliporfin VTP in two phases: an Induction Treatment Phase and a Maintenance Treatment Phase and will be followed up for up to an additional 48 months in the long term (non intervention) follow up phase with the specific duration depending on the patient's response to treatment
开始日期2021-03-22 |
申办/合作机构 Steba Biotech NV [+2] |
100 项与 帕利泊芬 相关的临床结果
登录后查看更多信息
100 项与 帕利泊芬 相关的转化医学
登录后查看更多信息
100 项与 帕利泊芬 相关的专利（医药）
登录后查看更多信息
77
项与 帕利泊芬 相关的文献（医药）2023-05-01·The Journal of urology
Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma
Article
作者: Tracey, Andrew T. ; Lin, Oscar ; Dalbagni, Guido ; Nogueira, Lucas M. ; Sjoberg, Daniel D. ; Pietzak, Eugene J. ; Alvim, Ricardo G. ; Solit, David B. ; Benfante, Nicole E. ; Demac, Quinlan ; Donat, S. Machele ; Bochner, Bernard H. ; Hakimi, A. Ari ; Yip, Wesley ; Reisz, Peter A. ; Kim, Kwanghee ; Coleman, Jonathan A. ; Vanden Berg, Rand W. ; Al-Ahmadie, Hikmat ; Scherz, Avigdor ; Bajorin, Dean F.
PURPOSE:
Vascular-targeted photodynamic therapy with the intravascular photosensitizing agent padeliporfin (WST-11/TOOKAD-Soluble) has demonstrated therapeutic efficacy as an ablative treatment for localized cancer with potential adaptation for endoscopic management of upper tract urothelial carcinoma. This Phase I trial (NCT03617003) evaluated the safety of vascular-targeted photodynamic therapy with WST-11 in upper tract urothelial carcinoma.
MATERIALS AND METHODS:
Nineteen patients underwent up to 2 endoscopic vascular-targeted photodynamic therapy treatments, with follow-up for up to 6 months. Patients who had residual or recurrent upper tract urothelial carcinoma (any grade/size) failing prior endoscopic treatment or unable or unwilling to undergo surgical resection were eligible for inclusion. The primary endpoint was to identify the maximally tolerated dose of laser light fluence. A dose escalation model was employed, with increasing light fluence (100-200 mW/cm) using a modified continual reassessment method. The secondary endpoint was treatment efficacy, defined by absence of visible tumor and negative urine cytology 30 days posttreatment.
RESULTS:
Fourteen (74%) patients received the maximally tolerated dose of 200 mW/cm, 2 (11%) of whom experienced a dose-limiting toxicity. The initial 30-day treatment response rate was 94% (50% complete, 44% partial). Eight patients underwent a second treatment, with a final observed 68% complete response rate. Leading toxicities were flank pain (79%) and hematuria (84%), which were transient. No ureteral strictures associated with treatment were identified during follow-up.
CONCLUSIONS:
Vascular-targeted photodynamic therapy with WST-11 has an acceptable safety profile with strong potential as an effective, kidney-sparing endoscopic management option for upper tract urothelial carcinoma. The recently initiated multicenter Phase 3 ENLIGHTED trial (NCT04620239) is expected to provide further evidence on this therapy.
2022-07-01·World journal of urology2区 · 医学
Alternative- and focal therapy trends for prostate cancer: a total population analysis of in-patient treatments in Germany from 2006 to 2019
2区 · 医学
Article
作者: Aksoy, Cem ; Heers, Hendrik ; Flegar, Luka ; Groeben, Christer ; Borkowetz, Angelika ; Zacharis, Aristeidis ; Eisenmenger, Nicole ; Derigs, Marcus ; Huber, Johannes
Abstract:
Purpose:
Focal therapy (FT) offers an alternative approach for prostate cancer (PCa) treatment in selected patients. However, little is known on its actual establishment in health care reality.
Patients and methods:
We defined FT as high-intensity focused ultrasound (HIFU), hyperthermia ablation, cryotherapy, transurethral ultrasound ablation (TULSA) or vascular-targeted photodynamic therapy (VTP) TOOKAD®. We analyzed the nationwide German hospital billing database for a PCa diagnosis in combination with FT. For analyses on the hospital level, we used the reimbursement.INFO tool based on hospitals’ quality reports. The study period was 2006 to 2019.
Results:
We identified 23,677 cases of FT from 2006 to 2019. Considering all PCa cases with surgery, radiotherapy or FT, the share of FT was stable at 4%. The annual caseload of FT increased to a maximum of 2653 cases in 2008 (p < 0.001) and then decreased to 1182 cases in 2014 (p < 0.001). Since 2015, the cases of FT remained on a plateau around 1400 cases per year. The share of HIFU was stable at 92–96% from 2006 to 2017 and decreased thereafter to 75% in 2019 (p = 0.015). In 2019, VTP-TOOKAD® increased to 11.5% and TULSA to 6%. In 2006, 21% (62/299) of urological departments performed FT and 20 departments reached > 20 FT procedures. In 2019, 16% (58/368) of urological departments performed FT and 7 departments reached > 20 FT. In 2019, 25 urological departments offered FT other than HIFU: 5 centers hyperthermia ablation, 11 centers VTP TOOKAD®, 3 centers cryotherapy, 6 centers TULSA.
Conclusion:
The FT development in Germany followed the Gartner hype cycle. While HIFU treatment is the most commonly performed FT, the share of newer FT modalities such as VTP-TOOKAD® and TULSA is remarkably increasing.
2022-06-01·Acta ophthalmologica3区 · 医学
Excimer laser‐assisted corneal epithelial pattern ablation for corneal cross‐linking
3区 · 医学
Article
作者: Scherz, Avigdor ; Brekelmans, Jurriaan ; Verma, Shwetabh ; Brandis, Alexander ; Arba‐Mosquera, Samuel ; Dickman, Mor M. ; Goldschmidt, Ruth ; Saelens, Isabelle E.Y. ; Berendschot, Tos T.J.M. ; Goz, Alexandra ; Marcovich, Arie L. ; Nuijts, Rudy M.M.A.
Abstract:
Purpose:
To determine corneal cross‐linking (CXL) efficacy and chromophore penetration after excimer laser‐assisted patterned de‐epithelialization.
Methods:
Two‐hundred‐twenty porcine eyes were de‐epithelialized ex vivo, either fully (mechanical; n = 88) or patterned (excimer laser; n = 132). Consecutively, corneas were impregnated with hypo‐ or hyperosmolar riboflavin (RF; n = 20, RF‐D; n = 40, respectively) or water‐soluble taurine (WST11; n = 40, and WST‐D; n = 40, respectively), or kept unimpregnated (n = 80). Sixty corneas were subsequently irradiated, inducing CXL, with paired contralateral eyes serving as controls. Outcome measurements included strip extensiometry to assess CXL efficacy, and spectrophotometry and fluorescence microscopy to determine stromal chromophore penetration.
Results:
All tested chromophores induced significant CXL (p < 0.001), ranging from 7.6% to 14.6%, with similar stiffening for all formulations (p = 0.60) and both de‐epithelialization methods (p = 0.56). Light transmittance was significantly lower (p < 0.001) after full compared with patterned de‐epithelialization. Stromal chromophore penetration was comparable between fully and patterned de‐epithelialized samples, with full penetration in RD and RF‐D samples and penetration depths measuring 591.7 ± 42.8 µm and 592.9 ± 63.5 µm for WST11 (p = 0.963) and 504.2 ± 43.2 µm and 488.8 ± 93.1 µm for WST‐D (p = 0.669), respectively.
Conclusions:
Excimer laser‐assisted patterned de‐epithelialization allows for effective CXL. Stromal chromophore concentration is, however, reduced, which may have safety implications given the need for sufficient UVA attenuation in RF/UVA CXL. The different safety profile of near‐infrared (NIR) may allow safe WST11/NIR CXL even with reduced stromal chromophore concentration values. In vivo studies are needed to evaluate the benefits and further assess safety of excimer laser‐assisted patterned de‐epithelialization for corneal CXL.
22
项与 帕利泊芬 相关的新闻（医药）2024-12-04
-- Complete response (CR) observed in 85% (17/20) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase -- -- Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase – TEL AVIV, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced updated interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporfin VTP treatment in patients with low-grade upper tract urothelial cancer (UTUC). These data will be presented at the 25th Annual Meeting of the Society of Urologic Oncology (SUO 2024) taking place December 4-6, 2024 in Dallas, Texas. “As data from the ENLIGHTED trial matures, we continue to be encouraged by compelling and sustained efficacy signals from treatment with Padeliporfin VTP,” said Eyal Morag, M.D., Chief Medical Officer of ImPact Biotech. “These results further underscore the potential for Padeliporfin VTP to transform the treatment paradigm in low-grade UTUC, offering efficacy in line with standard of care but without the associated risk of organ injury or loss. We look forward to sharing additional data from the ENLIGHTED trial and to progressing Padeliporfin VTP in other unresectable solid tumors in 2025.” As of July 22, 2024, the data cut-off for the poster presentation at SUO, 32 patients had begun treatment, of which 20 had completed ITP and were evaluable for efficacy.
Key updated preliminary results from the Phase 3 ENLIGHTED study of Padeliporfin VTP:
Clinical Profile:
17 of the 20 (85%) response-evaluable patients achieved a CR at the end of ITP. Safety and Tolerability Profile:
Padeliporfin VTP was well-tolerated with a safety profile consistent with the previous data obtained from the Phase 1 study and previously announced preliminary Phase 3 results. Adverse events (AEs) observed were primarily Grade 1 or 2, most of which were pain related, and all resolved within two to seven days. Only one patient experienced a Grade 3 serious adverse event that was related to the VTP therapy, which resolved within two days.There were no Grade 4 or 5 serious adverse events observed. ImPact continues to recruit for the ENLIGHTED study. As previously announced in September, the Company has exceeded 50% enrollment in the study and expects to complete enrollment by early 2025. Poster & Session Details:
Poster Title: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-grade Upper Tract Urothelial Cancer (LG UTUC): ENLIGHTENED Phase 3 studyPresenter: Vitaly Margulis, M.D., Chair in Urology, UT Southwestern Medical CenterPoster Number: 244Session Title: SUO24 Networking and Abstract Discussion SessionSession Date & Time: December 6, 2024, 1:45 PM CST About ENLIGHTEDThe Phase 3 ENLIGHTED study is a single arm, non-randomized, open-label, pivotal trial evaluating Padeliporfin VTP for the treatment of low-grade UTUC. Across 29 clinical sites globally, ImPact is targeting enrollment of up to 100 patients with new or recurrent low-grade, non-invasive UTUC of the kidney or ureter. The study consists of two parts – an Induction Treatment Phase (ITP) and Maintenance Treatment Phase (MTP) – across which Padeliporfin, a photosensitizing drug, is administered intravenously and VTP therapy is performed, via an outpatient endoscopy which applies a laser fiber illumination for 10 minutes in the proximity of the tumor, leading to local activation of Padeliporfin in the tumor. ITP consists of one-to-three treatments with VTP therapy at four-week intervals or until a complete response (CR) is achieved; MTP follows with standard-of-care treatment alongside VTP therapy administered every three months for up to 12 months. The study’s primary objective is to assess the response rate to Padeliporfin VTP treatment at the end of ITP, with secondary objectives evaluating safety, tolerability and duration of response.
About ImPact Biotech ImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug-device combination for selective ablation of unresectable solid tumors. The novel VTP platform delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment. Padeliporfin VTP is currently being evaluated in a pivotal Phase 3 study in low-grade upper tract urothelial carcinoma (UTUC) with earlier stage studies ongoing or planned in high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The Company has longstanding collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center and operations in the EU, Israel and the US. For more on ImPact Biotech Ltd., visit: www.impactbiotech.com and the ENLIGHTED clinical trial website (for the US): https://www.enlighted-study.com. Contacts Global Head of Business DevelopmentGuy Schmidtguy.schmidt@impactbiotech.com Precision AQJosh Rappaportjosh.rappaport@precisionaq.com
临床3期临床结果ASCO会议临床1期
2024-11-08
·药明康德
▎药明康德内容团队编辑
ImPact Biotech公司今天宣布了ENLIGHTED临床3期试验的最新中期结果。分析显示，高达86%接受其在研帕利泊芬（padeliporfin）血管靶向光动力（VTP）疗法治疗的低级别上尿路尿路上皮癌（UTUC）患者达到完全缓解（CR）。
ENLIGHTED研究是一项单一队列、非随机、开放标签的3期关键试验，旨在评估帕利泊芬VTP用于治疗低级别UTUC患者的疗效与安全性。该研究包括两个部分——诱导治疗阶段（ITP）和维持治疗阶段（MTP）。患者通过静脉注射光敏药物帕利泊芬，并通过门诊内镜检查在肿瘤附近应用激光光纤照明10分钟进行VTP治疗，这将导致肿瘤中帕利泊芬的局部激活。
截至2024年4月29日，已有22例患者接受治疗，其中14例患者已完成ITP并可评估疗效。分析显示，在14名可评估疗效的患者中，有12名（86%）在ITP结束时达到了CR。帕利泊芬VTP耐受性良好，其安全性与先前临床1期试验和之前公布的临床3期试验初步结果一致。观察到的不良事件（AE）主要为1级或2级，其中大部分与疼痛有关，且均在两到七天内消退。ImPact Biotech公司计划继续ENLIGHTED研究的患者招募。
▲帕利泊芬VTP疗法作用机制（图片来源：ImPact Biotech公司官网）
帕利泊芬VTP疗法是一种选择性消融不可切除实体瘤的微创药物-医疗器械组合疗法。该新型VTP平台通过光纤传递非热激光光源，在肿瘤微环境中局部激活帕利泊芬。除了消融肿瘤之外，帕利泊芬VTP疗法还被证明可以在动物模型中引发免疫激活。帕利泊芬VTP目前正在低级别上尿路上皮癌的关键3期研究中进行评估，同时在高级别UTUC、胰腺导管腺癌（PDAC）和非小细胞肺癌（NSCLC）中的早期研究也在进行或计划中。
▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放
参考资料：
[1] ImPact Biotech Presents Updated Interim Phase 3 Data from ENLIGHTED
Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024. Retrieved November 7,
2024 from https://www.globenewswire.com/news-release/2024/11/07/2976523/0/en/ImPact-Biotech-Presents-Updated-Interim-Phase-3-Data-from-ENLIGHTED-Study-of-Padeliporfin-VTP-in-Low-Grade-UTUC-at-EMUC-2024.html
免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。
版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。
分享，点赞，在看，聚焦全球生物医药健康创新
临床3期临床成功临床结果
2024-11-07
-- Complete response (CR) observed in 86% (12/14) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase --
-- Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase --
TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced updated interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporfin VTP treatment in patients with low-grade upper tract urothelial cancer (UTUC), at the 16th European Multidisciplinary Congress on Urological Cancers (EMUC 2024) taking place in Lisbon, Portugal.
“The overall profile and robustness of response to Padeliporfin VTP underscores its potential to reshape the therapeutic landscape in patients with UTUC,” said Gautier Marcq, M.D., Assistant Professor Urology Department, Centre de Universitaire Régional Hospitalier de Lille, Lille, France and an investigator in the ENLIGHTED study. “Current standards of care in this indication often require an invasive surgical intervention, resulting in many cases in organ injury or loss, or a burdensome therapeutic regimen that fails to match surgery in efficacy. These results highlight Padeliporfin VTP as a compelling alternative, which may not require patients to compromise between sparing their organs and treating their cancer. I am encouraged by these data and look forward to additional analyses towards improved treatment and better outcomes for patients with UTUC.”
The Phase 3 ENLIGHTED study is a single arm, non-randomized, open-label, pivotal trial evaluating Padeliporfin VTP for the treatment of low-grade UTUC. Across 29 clinical sites globally, ImPact is targeting enrollment of up to 100 patients with new or recurrent low-grade, non-invasive UTUC of the kidney or ureter. The study consists of two parts – an Induction Treatment Phase (ITP) and Maintenance Treatment Phase (MTP) – across which Padeliporfin, a photosensitizing drug, is administered intravenously and VTP therapy is performed, via an outpatient endoscopy which applies a laser fiber illumination for 10 minutes in the proximity of the tumor, leading to local activation of Padeliporfin in the tumor. ITP consists of one-to-three treatments with VTP therapy at four-week intervals or until a complete response (CR) is achieved; MTP follows with standard-of-care treatment alongside VTP therapy administered every three months for up to 12 months. The study’s primary objective is to assess the response rate to Padeliporfin VTP treatment at the end of ITP, with secondary objectives evaluating safety, tolerability and duration of response.
As of April 29, 2024, the data cut-off for this presentation, 22 patients had begun treatment, of which 14 had completed ITP and were evaluable for efficacy.
Key updated preliminary results from the Phase 3 ENLIGHTED study of Padeliporfin VTP:
Clinical Profile:
Twelve of the 14 (86%) response-evaluable patients achieved a CR at the end of ITP.
Safety and Tolerability Profile:
Padeliporfin VTP was well-tolerated with a safety profile consistent with the previous data obtained from the Phase 1 study and previously announced preliminary Phase 3 results. Adverse events (AEs) observed were primarily Grade 1 or 2, most of which were pain related, and all resolved within two to seven days. Only one patient experienced a Grade 3 serious adverse event that was related to the VTP therapy, which resolved within two days.There were no Grade 4 or 5 serious adverse events observed.
“We are highly encouraged to see consistent patient responses to Padeliporfin VTP treatment as we progress the ENLIGHTED Phase 3 study,” said Eyal Morag, M.D., Chief Medical Officer of ImPact Biotech. “This expansion of our dataset presented in June further establishes the potential for Padeliporfin VTP to transform the treatment landscape for UTUC, by providing efficacy in line with standard of care without incurring risk of organ injury or loss. With trial enrollment on track to conclude by early 2025, we look forward to providing subsequent data updates that we expect to provide basis for registration of Padeliporfin VTP in low grade UTUC. In parallel, we will look to replicate this effect in other unresectable solid tumors, beginning with our planned Phase 1 study in PDAC.”
ImPact continues to recruit for the ENLIGHTED study. As previously announced in September, the Company has exceeded 50% enrollment in the study and expects to complete enrollment by early 2025.
The poster will be viewable during the EMUC24 Networking and Abstract Discussion Session on Saturday, November 9, 2024, 17:30 GMT.
About ImPact Biotech
ImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug-device combination for selective ablation of unresectable solid tumors. The novel VTP platform delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment. Padeliporfin VTP is currently being evaluated in a pivotal Phase 3 study in low-grade upper tract urothelial carcinoma (UTUC) with earlier stage studies ongoing or planned in high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The Company has longstanding collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center and operations in the EU, Israel and the US. For more on ImPact Biotech Ltd., visit: www.impactbiotech.com and the ENLIGHTED clinical trial website (for the US): https://www.enlighted-study.com.
Contacts
Global Head of Business DevelopmentGuy Schmidtguy.schmidt@impactbiotech.com
Precision AQJosh Rappaportjosh.rappaport@precisionaq.com
临床3期临床结果临床1期
100 项与 帕利泊芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺腺癌 | 欧盟 | 2017-11-10 | |
| 前列腺腺癌 | 冰岛 | 2017-11-10 | |
| 前列腺腺癌 | 列支敦士登 | 2017-11-10 | |
| 前列腺腺癌 | 挪威 | 2017-11-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 局限性前列腺癌 | 临床3期 | 墨西哥 | 2013-05-01 | |
| 局限性前列腺癌 | 临床3期 | 巴拿马 | 2013-05-01 | |
| 局限性前列腺癌 | 临床3期 | 秘鲁 | 2013-05-01 | |
| 前列腺癌 | 临床3期 | 比利时 | 2011-02-01 | |
| 前列腺癌 | 临床3期 | 芬兰 | 2011-02-01 | |
| 前列腺癌 | 临床3期 | 法国 | 2011-02-01 | |
| 前列腺癌 | 临床3期 | 德国 | 2011-02-01 | |
| 前列腺癌 | 临床3期 | 意大利 | 2011-02-01 | |
| 前列腺癌 | 临床3期 | 荷兰 | 2011-02-01 | |
| 前列腺癌 | 临床3期 | 西班牙 | 2011-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 20 | 範網鹹構窪憲鹹膚製憲(鑰壓憲選獵鑰簾鹹衊壓) = 鏇獵醖醖壓淵鹹壓築製 糧遞齋鑰顧築遞艱顧齋 (夢淵願憲鬱簾糧憲壓醖 ) | 积极 | 2024-12-04 | |||
临床3期 | 14 | 夢膚獵製築願蓋餘繭鑰(襯糧鏇顧遞鹽網顧鑰淵) = 獵醖艱網窪艱鬱膚網餘 構顧範鏇襯襯構壓簾製 (廠繭築繭繭構鏇窪蓋鏇 ) | 积极 | 2024-11-07 | |||
临床3期 | 13 | Padeliporfin | 製醖壓壓鬱窪壓憲襯鹹(壓窪廠膚糧積夢顧膚齋) = 製選願顧簾壓窪顧鹹觸 窪鬱鏇積糧憲蓋觸壓衊 (鬱鹹選廠窪鹹網蓋襯鏇 ) 更多 | 积极 | 2024-06-02 | ||
临床3期 | 9 | 糧製鏇憲製製觸網範糧(顧夢鏇醖窪膚醖鹽鹹獵) = 鑰襯願製築獵簾繭壓憲 構窪獵繭鬱夢齋夢選衊 (簾廠選鹹鹹構構膚蓋襯 ) | 积极 | 2024-05-06 | |||
临床1期 | 14 | phototherapy +WST11 | 壓憲觸憲遞廠觸範鹹壓(繭遞範窪醖觸醖選壓衊) = 廠蓋鹽鏇繭夢網製醖獵 鹹夢壓鹹壓築鬱鏇鬱顧 (選遞選糧繭壓衊齋範夢 ) 更多 | 积极 | 2021-02-20 | ||
临床3期 | - | 遞繭窪壓觸範遞範簾憲(淵夢齋醖衊膚鹹淵繭餘) = 選膚衊鬱網鏇鏇鏇窪觸 鏇選積願壓構鹹廠齋鑰 (鹽簾淵築鹹膚顧鏇積築 ) 更多 | 积极 | 2017-02-01 | |||
active surveillance | 遞繭窪壓觸範遞範簾憲(淵夢齋醖衊膚鹹淵繭餘) = 鏇淵觸衊顧網淵築願繭 鏇選積願壓構鹹廠齋鑰 (鹽簾淵築鹹膚顧鏇積築 ) 更多 | ||||||
临床1/2期 | 30 | WST11 vascular targeted photodynamic therapy | 鏇鹽艱選淵觸願膚鹽憲(蓋糧廠襯網壓遞衊壓糧) = 願醖繭鏇繭顧襯鏇網窪 艱蓋製餘齋襯製淵鑰壓 (衊糧窪網願構繭製糧顧 ) | - | 2016-10-01 | ||
N/A | - | 16 | 構襯淵夢遞鏇糧網餘膚(夢憲鑰構網簾齋鹹鑰醖) = Chronic ablations showed the development of cortical fibrosis 獵廠蓋壓選鏇鹹壓顧範 (鬱製積蓋窪繭壓網選膚 ) 更多 | - | 2014-04-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用